Report Detail
Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) Global Clinical Trials Review, H2, 2019
- RnM3864448 |
- 10 January, 2020 |
- Global |
- 52 Pages |
- GlobalData |
- Pharma & Healthcare
Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) Global Clinical Trials Review, H2, 2019
Summary
GlobalData's clinical trial report, “Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) Global Clinical Trials Review, H2, 2019" provides an overview of Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) clinical trials scenario. This report provides top line data relating to the clinical trials on Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table of Contents
List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Clinical Trials by G7 Countries: Proportion of Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) to Ophthalmology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) to Ophthalmology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) Therapeutics Clinical Trials 28
Prominent Drugs 29
Latest Clinical Trials News on Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 30
Oct 09, 2019: GenSight Biologics reports evidence of GS010 DNA transfer to contralateral eye of primates unilaterally injected with GS010 Gene Therapy 30
Oct 08, 2019: GenSight Biologics to present new GS010 data at the 2019 Annual Meeting of the American Academy of Ophthalmology 30
Sep 24, 2019: GenSight reports first results from week 96 of RESCUE Phase III trial 31
Clinical Trial Profile Snapshots 32
Appendix 49
Abbreviations 49
Definitions 49
Research Methodology 50
Secondary Research 50
About GlobalData 51
Contact Us 51
Source 52
Summary:
Get latest Market Research Reports on Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy). Industry analysis & Market Report on Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) is a syndicated market report, published as Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) Global Clinical Trials Review, H2, 2019. It is complete Research Study and Industry Analysis of Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
